去势抵抗性前列腺癌高表达成纤维细胞激活蛋白支持FAPI分子诊疗应用
该研究用组织微阵列免疫组化评估94例不同阶段前列腺癌组织的成纤维细胞激活蛋白(FAP)表达,发现FAP表达随疾病进展显著升高,CRPC最高;3例晚期CRPC或NEPC患者[68Ga]Ga-FAPI-04 PET/CT呈高阳性,支持FAPI分子诊疗用于CRPC。
要点
- FAP组织表达随前列腺癌疾病进展显著升高,CRPC组最高。
- 3例晚期CRPC或NEPC患者[68Ga]Ga-FAPI-04 PET/CT呈高阳性。
- FAP表达升高支持在CRPC中应用FAPI分子诊疗。
核心结论
- 前列腺癌组织FAP表达随疾病进展显著升高,CRPC最高,支持FAPI分子诊疗用于CRPC。
研究设计与样本
- 构建94例不同阶段前列腺癌组织的组织微阵列,用抗FAP单克隆抗体染色并以阳性像素计数算法(H-Index)比较各组FAP表达。
- 另对3例晚期CRPC或NEPC患者行[68Ga]Ga-FAPI-04 PET/CT并分析PET阳性。
主要发现
- 良性组织、原发前列腺癌、根治性前列腺切除术前新辅助雄激素剥夺治疗、CRPC和NEPC的平均H-index分别为0.018、0.031、0.042、0.076和0.051,提示FAP表达随疾病进展显著升高。
- 3例晚期CRPC或NEPC患者[68Ga]Ga-FAPI-04 PET/CT呈高阳性。
临床怎么用
- 对晚期CRPC可考虑[68Ga]Ga-FAPI-04 PET/CT评估FAP表达,为FAPI分子诊疗筛选候选患者。
局限性
- PET/CT验证仅3例晚期CRPC或NEPC患者,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate fibroblast-activation-protein (FAP) expression in different clinical stages of prostate cancer (PC) with regards to utility of [68 Ga]Ga-FAPI-04 PET/CT imaging in patients with castration-resistant PC (CRPC). METHODS: Tissue microarrays (TMAs) were constructed from prostatic tissue from 94 patients at different stages of PC (primary PC, patients undergoing neoadjuvant androgen deprivation therapy, CRPC, and neuroendocrine PC (NEPC)) and were stained with anti-FAP monoclonal antibody. A positive pixel count algorithm (H-Index) was used to compare FAP expression between the groups. Additionally, three men with advanced CRPC or NEPC underwent [68 Ga]Ga-FAPI-04 PET/CT, and PET positivity was analyzed. RESULTS: The mean H-index for benign tissue, primary PC, neoadjuvant androgen deprivation therapy before radical prostatectomy, CRPC, and NEPC was 0.018, 0.031, 0.042, 0.076, and 0.051, respectively, indicating a significant rise in FAP expression with advancement of disease. Corroborating these findings [68 Ga]Ga-FAPI-04 PET/CT was highly positive in men with advanced CRPC. CONCLUSION: Increased FAP tissue expression supports the use of FAP inhibitor (FAPI)-molecular theranostics in CRPC.
引用
- Kesch C, Yirga L, Dendl K, et al. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021. PMID: 34226953. doi:10.1007/s00259-021-05423-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。